Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

Jin-An Jiao Biography and Net Worth

VP of HCW Biologics

Jin-an Jiao has served as our Vice President of Development since May 2019. Prior to joining our company, Dr. Jiao served as the Vice President of Development at Altor BioScience Corporation from March 2017 to May 2019; the Chief Scientific Officer at SAB Biotherapeutics from July 2014 to March 2017; Head of Product Development at Sanford Applied Biosciences from December 2013 to July 2014; the Executive Vice President of Product Development and Manufacturing at Hematech Inc. from March 2003 to December 2013; the Director of Protein Development at Sunol Molecular Corporation from May 1995 to March 2003; and a group leader of protein biochemistry at Baxter Diagnostics, Baxter International Inc.’s largest subsidiary, from 1992 to 1995. Dr. Jiao received his Ph.D. in Biochemistry from University of Nebraska-Lincoln, and completed his postdoctoral training at the University of California, Berkeley.

How do I contact Jin-An Jiao?: The corporate mailing address for Mr. Jiao and other HCW Biologics executives is , , . HCW Biologics can also be reached via phone at 954-842-2024 and via email at [email protected]. Learn More on Jin-An Jiao's contact information.
Has Jin-An Jiao been buying or selling shares of HCW Biologics?: Jin-An Jiao has not been actively trading shares of HCW Biologics within the last three months. Most recently, on Monday, December 6th, Jin-An Jiao bought 10,000 shares of HCW Biologics stock. The stock was acquired at an average cost of $2.42 per share, with a total value of $24,200.00. Learn More on Jin-An Jiao's trading history.
Are insiders buying or selling shares of HCW Biologics?: During the last year, HCW Biologics insiders bought shares 19 times. They purchased a total of 171,008 shares worth more than $307,105.60. The most recent insider tranaction occured on September, 14th when CEO Hing C Wong bought 1,800 shares worth more than $3,744.00. Insiders at HCW Biologics own 45.3% of the company. Learn More about insider trades at HCW Biologics.
Information on this page was last updated on 9/14/2023.

Jin-An Jiao Insider Trading History at HCW Biologics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/6/2021	Buy	10,000	$2.42	$24,200.00

Jin-An Jiao Buying and Selling Activity at HCW Biologics

HCW Biologics Company Overview

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

Today's Range

Now: $1.66

$1.50

$1.67

50 Day Range

MA: $1.51

$1.12

$1.77

2 Week Range

Now: $1.66

$0.91

$2.32

Volume

2,566 shs

Average Volume

15,819 shs

Market Capitalization

$62.78 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.97

The “Perfect Storm” for Gold

From Gold Safe Exchange | Ad